These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Drug development parameters for functional imaging in neurosciences. Otte A; Wink K Hell J Nucl Med; 2007; 10(2):80-1. PubMed ID: 17684581 [TBL] [Abstract][Full Text] [Related]
26. Quality by design in lead optimization: a new strategy to address productivity in drug discovery. Rossi T; Braggio S Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263 [TBL] [Abstract][Full Text] [Related]
27. The extinction of drugs for clinical research: Can the ECNP medicines chest save them? Nutt D; Kilpatrick G; Hayes A Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534 [No Abstract] [Full Text] [Related]
28. Targeting neuronal function for CNS drug discovery. Hempel CM; Werley CA; Dempsey GT; Gerber DJ Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082 [TBL] [Abstract][Full Text] [Related]
30. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation. Hellyer S; Leach K; Gregory KJ Curr Opin Pharmacol; 2017 Feb; 32():49-55. PubMed ID: 27842256 [TBL] [Abstract][Full Text] [Related]
31. The discovery of potent agonists for GPR88, an orphan GPCR, for the potential treatment of CNS disorders. Bi Y; Dzierba CD; Fink C; Garcia Y; Green M; Han J; Kwon S; Kumi G; Liang Z; Liu Y; Qiao Y; Zhang Y; Zipp G; Burford N; Ferrante M; Bertekap R; Lewis M; Cacace A; Westphal RS; Kimball D; Bronson JJ; Macor JE Bioorg Med Chem Lett; 2015 Apr; 25(7):1443-7. PubMed ID: 25754495 [TBL] [Abstract][Full Text] [Related]
32. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases. O'Sullivan S; Dev KK Neuropharmacology; 2017 Feb; 113(Pt B):597-607. PubMed ID: 27825807 [TBL] [Abstract][Full Text] [Related]
33. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems Biology. Mei H; Feng G; Zhu J; Lin S; Qiu Y; Wang Y; Xia T Methods Mol Biol; 2016; 1303():531-47. PubMed ID: 26235090 [TBL] [Abstract][Full Text] [Related]
34. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511 [TBL] [Abstract][Full Text] [Related]
35. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature. Amigoni F; Legnaghi E; Pevarello P Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782 [TBL] [Abstract][Full Text] [Related]
36. Cell adhesion molecules: druggable targets for modulating the connectome and brain disorders? Uhl GR; Drgonova J Neuropsychopharmacology; 2014 Jan; 39(1):235. PubMed ID: 24317312 [No Abstract] [Full Text] [Related]
37. Research use exemptions to patent infringement for drug discovery and development in the United States. Russo AA; Johnson J Cold Spring Harb Perspect Med; 2014 Oct; 5(2):a020933. PubMed ID: 25359549 [TBL] [Abstract][Full Text] [Related]
38. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases]. Kanazawa T Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986 [TBL] [Abstract][Full Text] [Related]
39. P2X7 antagonists for CNS indications: recent patent disclosures. Pevarello P; Bovolenta S; Tarroni P; Za L; Severi E; Torino D; Vitalone R Pharm Pat Anal; 2017 Mar; 6(2):61-76. PubMed ID: 28248151 [TBL] [Abstract][Full Text] [Related]
40. Discovery and Development of Muscarinic Acetylcholine M Takai K; Enomoto T Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]